Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial
A single dose of NVX-CoV2705 induced a rapid and robust anti-SARS-CoV-2 immune response against the Omicron JN.1 and other circulating variants and had an acceptable safety profile. https://clinicaltrials.gov/study/NCT06409663.
Authors
- Katia Alves (ORCID: https://orcid.org/0000-0002-4181-2051)
- MingZhu Zhu
- Joyce S. Plested (ORCID: https://orcid.org/0009-0007-0283-0779)
- Raburn M. Mallory (ORCID: https://orcid.org/0000-0002-2563-9981)
- Raj Kalkeri (ORCID: https://orcid.org/0000-0002-1188-277X)
- Irene McKnight
- Zhaohui Cai (ORCID: https://orcid.org/0000-0001-5935-3570)
- Shane Cloney-Clark
- Fernando Noriega
- Joy Nelson
- Alex Kouassi
- Ashika Ahmed
Institutions
- Novavax (United States) (US)
Publication Details
- Journal
- Vaccine
- Published
- 2025-12-26
- DOI
- https://doi.org/10.1016/j.vaccine.2025.128164
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40